National Academies Press: OpenBook
« Previous: Implementing a National Cancer Clinical Trials System for the 21st Century
Suggested Citation:"References." Institute of Medicine. 2011. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13154.
×

References

Abrams, J., R. Erwin, G. Fyfe, R. L. Schilsky, and R. Temple. 2009. Data submission standards and evidence requirements. Presented at the Conference on Clinical Cancer Research, Panel 1. Engelberg Center for Health Care Reform, Brookings Institution, Washington, DC.

ACS CAN (American Cancer Society Cancer Action Network). 2009. Barriers to provider participation in clinical cancer trials: Potential policy solutions. Washington, DC: American Cancer Society Cancer Action Network.

C-Change and the Coalition for Cancer Cooperative Groups. 2006. Enhancing cancer treatment through improved understanding of the critical components, economics, and barriers of cancer clinical trials. Washington, DC: C-Change; Philadelphia, PA: Coalition of Cancer Cooperative Groups.

Cheng, S. K., M. Dietrich, S. Finnigan, A. Sandler, J. Crites, L. Ferranti, A. Wu, and D. Dilts. 2009. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. Journal of Clinical Oncology 200ASCO Annual Meeting Proceedings 27(18 Suppl.):CRA6509.

CTEP (Cancer Therapy Evaluation Program). 2011. CTEP intellectual property option to collaborator. Federal Register 76(48):13404-13410.

Federal Register. 2011. Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators. Volume 76, Number 143. http://www.gpo.gov/fdsys/pkg/FR-2011-07-26/html/2011-18792.htm (accessed July 27, 2011).

Flaherty, K. T., I. Puzanov, K. B. Kim, A. Riba, G. A. McArthur, J. A. Sosman, P. J. O’Dwyer, R. L. Lee, J. F. Grippo, K. Nolop, and P. B. Chapman. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine 26;363(9):809-819.

Gianni, L. 2009. Anthracyclines and early breast cancer: The end of an era? Journal of Clinical Oncology 27(8):1155-1157.

Suggested Citation:"References." Institute of Medicine. 2011. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13154.
×

Hautala, J. 2010. Cooperative Group Financial, Organizational and Management Analysis. Presentation to the NCI Clinical Trials and Translational Research Advisory Committee, September 21. http://deainfo.nci.nih.gov/advisory/ctac/0910/presentations/Hautala.pdf (accessed April 21, 2011).

IOM (Institute of Medicine). 2010. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press.

Jones, S., F. A. Holmes, J. O’Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, W. J. Hyman, D. A. Richards, R. G. Mennel, K. A. Boehm, W. G. Meyer, L. Asmar, D. Mackey, S. Riedel, H. Muss, and M. A. Savin. 2009. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared to doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. Journal of Clinical Oncology 27(8):1177-1183.

Kanarek, N. F., H. L. Tsai, S. Metzger-Gaud, D. Damron, A. Guseynova, J. F. Klamerus, and C. M. Rudin. 2010. Geographic proximity and racial disparities in cancer clinical trial participation. Journal of the National Comprehensive Cancer Network 8(12):1343-1351.

Klabunde, C. N., N. L. Keating, A. L. Potosky, A. Ambs, Y. He, M. C. Hornbrook, and P. A. Ganz. 2011. A population-based assessment of specialty physician involvement in cancer clinical trials. Journal of the National Cancer Institute 103(5):384-397.

Klamerus, J. F., S. S. Bruinooge, X. Ye, M. L. Klamerus, D. Damron, D. Lansey, J. C. Lowery, L. A. Diaz, Jr., J. G. Ford, N. Kanarek, and C. M. Rudin. 2010. The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clinical Cancer Research 16(24):5997-6003.

Korn, E. L., B. Freidlin, M. Mooney, and J. S. Abrams. 2010. Accrual experience of National Cancer Institute Cooperative Group Phase III trials activated from 2000 to 2007. Journal of Clinical Oncology 28(35):5197-5201.

Kwak, E. L., Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, and A. J. Iafrate. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine 363(18):1693-1703.

Moss, A. J., C. W. Francis, and D. Ryan. 2011. Collaborative clinical trials. New England Journal of Medicine 364(9):789-791.

NCI (National Cancer Institute). 2005. Report of the clinical trials working group of the National Cancer Advisory Board: Restructuring the National Cancer Clinical Trials Enterprise. Bethesda, MD: National Cancer Institute.

———. 2010. Report of the operational efficiency working group of the Clinical Trials and Translational Research Advisory Committee: Compressing the timeline for cancer clinical trial activation. Bethesda, MD: National Cancer Institute.

Perry, M. C., R. L. Comis, and R. L. Schilsky. 2008. Introduction: Contributions of the cooperative groups. Seminars in Oncology 35(5):459.

Research!America. 2010. Research enterprise survey. http://www.researchamerica.org/uploads/ResearchEnterprisePoll.pdf (accessed April 20, 2010).

Suggested Citation:"References." Institute of Medicine. 2011. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13154.
×

Schroen, A. T., G. R. Petroni, H. Wang, B. Djulbegovis, C. L., Slingluff, X. F. Wang, R. Gray, D. J. Sargent, W. Cronin, and J. Benedetti. 2009. Challenges to accrual predictions to Phase III cancer clinical trials: A survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Journal of Clinical Oncology 27:15s (suppl; abstr 6562).

Sood, A., K. Prasad, L. Chhatwani, E. Shinozaki, S. Cha, L. Loehrer, and D. Wahner-Roedler. 2009. Patients’ attitudes and preferences about participation and recruitment strategies in clinical trials. Mayo Clinical Proceedings 84(3):243-247.

Stunkel, L., M. Benson, L. McLellan, N. Sinaii, Bedarida G., E. Emanuel, and C. Grady. 2010. Comprehension and informed consent: Assessing the effect of a short consent form. IRB Ethics and Human Research 32(4):1-9.

Su, S. C., N. Kanarek, M. G. Fox, A. Guseynova, S. Crow, and S. Piantadosi. 2010. Spatial analyses identify the geographic source of patients at a National Cancer Institute comprehensive cancer center. Clinical Cancer Research 16(3):1065-1072.

Suggested Citation:"References." Institute of Medicine. 2011. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13154.
×

This page intentionally left blank.

Suggested Citation:"References." Institute of Medicine. 2011. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13154.
×
Page 91
Suggested Citation:"References." Institute of Medicine. 2011. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13154.
×
Page 92
Suggested Citation:"References." Institute of Medicine. 2011. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13154.
×
Page 93
Suggested Citation:"References." Institute of Medicine. 2011. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13154.
×
Page 94
Next: Acronyms »
Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary Get This Book
×
Buy Paperback | $39.00 Buy Ebook | $31.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Clinical trials enable scientific discoveries to advance patient care, in addition to informing and guiding subsequent research. The National Cancer Institute's (NCI's) Clinical Trials Cooperative Group Program works to advance patient care and research. The Cooperative Group Program has been instrumental in establishing the standards for cancer patient care and clinical research methods. Despite broad participation in the program, financial strain and procedural burdens limit the ability of the Cooperative Group Program to undertake medical practice-changing clinical research.

Thus, the Institute of Medicine's (IOM's) National Cancer Policy Forum and the American Society of Clinical Oncology held a workshop on March 21, 2011 to follow up on the 2010 IOM report, A National Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, which made recommendations to strengthen the NCI Cooperative Group Program. In keeping with the established commitment to excellence Implementing a National Cancer Clinical Trials System for the 21st Century outlines how to improve the current system by incorporating innovative science and trial design into cancer clinical trials. It also examines the impact of increasing quality in regards to speed, efficiency, design, launch, and conduct, as well as improving prioritization, and incentivized participation.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!